ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,48%
Bitcoin
98.109,59
1,22%
Brent Oil
76,495
0,84%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) Notícias

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CGEM
DataHoraFonteTítuloCódigoCompanhia
20/12/202419:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
14/11/202419:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
14/11/202412:01GlobeNewswire Inc.Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202416:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202409:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
07/11/202409:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202409:00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/11/202409:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
04/11/202409:00GlobeNewswire Inc.Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/10/202408:00GlobeNewswire Inc.Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
17/09/202408:00GlobeNewswire Inc.Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
16/09/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
14/09/202405:15GlobeNewswire Inc.Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024NASDAQ:CGEMCullinan Therapeutics Inc
05/09/202417:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
28/08/202409:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
08/08/202408:00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/06/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
04/06/202418:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
01/06/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
24/05/202409:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202418:04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202417:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202408:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202407:42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202407:40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
15/05/202417:05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
29/04/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
24/04/202411:09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/04/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
16/04/202407:59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CGEM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
GFSA3
GAFISA ON
BOV
RCSL4
RECRUSUL PN
BOV
AMOB3
Automob Participacoes ON
BOV
AZEV4
AZEVEDO PN
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
COGN3
COGNA ON
BOV
RAIZ4
Raizen S.A PN
BOV
AMER3
Americanas ON
BOV
FICT3
Fictor Alimentos ON
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
USIM5
USIMINAS PNA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados